On Friday, Principal Financial Group Inc (NYSE:PFG)’s shares inclined 0.19% to $51.88.
Principal Financial Group Inc (PFG) Chairman Blair Pickerell to the life insurer’s board.
Pickerell becomes a director effective Aug. 17, Des Moines, Iowa-based Principal said in a statement.
Principal joins insurers adding asset managers to their boards as near-record-low interest rates pressure investment income. Aflac Inc. named Thomas Kenny, a former fund manager at Goldman Sachs Group Inc., as a director in February. Unum Group designated former Fidelity Investments head of asset administration Ronald O’Hanley to its board the same month.
Blair brings a valuable perspective to the board with his work in asset administration in large, global organizations,” Larry Zimpleman, Principal’s chairman and chief executive officer, said in the statement.
Principal Financial Group, Inc. provides retirement, asset administration, and insurance products and services. It operates through Retirement and Investor Services, Principal Global Investors, Principal International, and U.S. Insurance Solutions segments. The Retirement and Investor Services segment provides a portfolio of asset accumulation products and services for retirement savings and investment to businesses, institutional clients, and employees of business and other individuals. It offers products and services for defined contribution pension plans, counting 401(k) and 403(b) plans, defined benefit pension plans, nonqualified executive benefit plans, and employee stock ownership plans; investment-only products; and annuities, mutual funds, and bank products. The Principal Global Investors segment provides equity, fixed income, real estate, and other alternative investments, in addition to asset allocation, stable value administration, and other structured investment strategies.
Plains GP Holdings LP (NYSE:PAGP)’s shares gained 4.36% to $28.03.
Plains All American Pipeline, L.P. (PAA), a partner of Plains GP Holdings LP (PAGP) practiced a crude oil release from its 24-inch Las Flores to Gaviota Pipeline (Line 901) in Santa Barbara County, California. The pipeline was transporting crude oil from third party storage tanks located in Las Flores Canyon to Plains’ Gaviota Pump Station. Some of the released oil reached a drainage culvert leading to the Pacific Ocean at the Refugio State Beach and influenced the ocean water and the local shoreline. Plains shut down the pipeline and initiated its emergency response plan. No human injuries have been stated, but there have been reports of impacts to wildlife. The cause of the leak is being investigated and although the exact amount of released oil has not yet been finally determined, Plains presently estimates that the amount of released crude oil could be as high as about 2,400 barrels.
PAA is working closely with local, state and federal government agencies and first responders to clean up and remediate the affected areas. On May 21, 2015, Plains received a corrective action order from the United States Department of Transportation’s Pipeline and Hazardous Materials Safety Administration (“PHMSA”) requiring Plains to shut down, purge, review, remediate and test the pipeline. Among other requirements, the order also obligates Plains to conduct a root cause failure analysis and present remedial work plans and restart plans to PHMSA prior to returning the line to service. PAA fully intends to comply with the PHMSA order and to cooperate with any other governmental investigations regardingor arising out of the release.
Plains GP Holdings, L.P., through its interest in Plains AAP, L.P., owns and operates midstream energy infrastructure and provides logistics services for crude oil, natural gas liquids, natural gas, and refined products in the United States and Canada. The company operates through three segments: Transportation, Facilities, and Supply and Logistics.
At the end of Friday’s trade, OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI)‘s shares surged 5.58% to $2.65.
OncoGenex Pharmaceuticals, Inc. (OGXI) declared that results from a retrospective analysis of the Phase 3 SYNERGY trial showed a benefit with custirsen therapy in men with metastatic castrate-resistant prostate cancer (CRPC) who had a poor prognosis. The analysis, exploring the effect of clusterin inhibition in men at risk for poor outcomes, showed that over 40 percent of men in the trial had at least two of five common risk factors for poor prognosis. In these men, the analysis found a 27 percent lower risk of death when custirsen was used in combination with first-line docetaxel contrast to docetaxel alone. These results were presented at the 51st A.
Custirsen is designed to block the production of the protein clusterin, which is overexpressed in a number of cancers and has been linked to faster rates of cancer progression, treatment resistance and shorter survival duration in patients. OncoGenex, in partnershipwith study investigators, have defined a simple 5-criteria characterization for poor prognosis in prostate cancer based on the SYNERGY trial, which comprise: poor performance status, elevated prostate specific antigen (PSA), elevated lactate dehyrdogenase (LDH), reduced hemoglobin, and the presence of liver metastasis. The findings from the SYNERGY study show a preferential effect in patients who are more vulnerable to poor outcomes and may reveal the patient population most likely to benefit from clusterin inhibition in other studies.
OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients. The company’s product candidates comprise Custirsen that is in Phase III clinical development for the treatment in men with metastatic castrate-resistant prostate cancer, in addition to in patients with non-small cell lung cancer; and Apatorsen, which is in two Phase I and seven randomized Phase II trials for the treatment of bladder, lung, pancreatic, and prostate cancers.
Dejour Energy Inc (USA) (NYSEMKT:DEJ), ended its Friday’s trading session with 10.09% gain, and closed at $0.132.
Dejour Energy Inc (USA) (DEJ) declared that it has received notification on June 1, 2015 from the NYSE MKT (“the Exchange”) that it has regained compliance with Section 1003(a)(iv) of the Exchange’s Company Guide as of the end of the maximum eighteen month cure period that ended on May 22, 2015. This requirement addresses a company’s ability to continue to operate as a going concern.
The Company noted that the Exchange is ongoing to actively monitor its liquidity position on an ongoing basis, counting its progress on several near term milestones communicated to the Exchange in connection with its business plan.
Dejour Energy Inc. engages in acquiring, exploring, and developing energy projects with a focus on oil and gas exploration in Canada and the United States. It holds interests in about 60,100 net acres of oil and gas leases in the Peace River Arch of northwestern British Columbia and northeastern Alberta, Canada; and the Piceance, Paradox, and Uinta Basins in the U.S. Rocky Mountains.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
